Insights

Innovative Diagnostic Portfolio Biohit offers a comprehensive range of early diagnosis products for gastrointestinal diseases, including GastroPanel, quick tests for lactose intolerance and Helicobacter pylori, and fecal occult blood tests, providing multiple opportunities for healthcare providers and laboratories to incorporate advanced diagnostic solutions.

Global Market Presence With subsidiaries in China, Italy, and the United Kingdom, Biohit’s international footprint allows for expansion of sales channels and regional partnerships, particularly in markets seeking innovative and early diagnostic tools.

Focus on Carcinogen Reduction The company’s development of Acetium, aimed at reducing carcinogenic acetaldehyde, represents a unique selling point for health-conscious consumers and healthcare providers focused on cancer prevention and gastrointestinal health.

Financial Growth Potential With revenues ranging between 100 and 250 million USD and a listing on NASDAQ OMX Helsinki, Biohit’s financial stability and growth trajectory present strong prospects for sales collaborations and investment opportunities.

Research-Driven Innovation Biohit’s commitment to scientific knowledge dissemination and product innovation, especially related to carcinogen awareness and early disease detection, offers partnership opportunities with research institutions and medical professionals aiming to enhance healthcare solutions.

Similar companies to Biohit Oyj

Biohit Oyj Tech Stack

Media & News

Biohit Oyj's Email Address Formats

Biohit Oyj uses at least 1 format(s):
Biohit Oyj Email FormatsExamplePercentage
First.Last@biohit.fiJohn.Doe@biohit.fi
96%
Last.First@biohit.fiDoe.John@biohit.fi
1%
FLast@biohit.fiJDoe@biohit.fi
2%
First@biohit.fiJohn@biohit.fi
1%

Frequently Asked Questions

Where is Biohit Oyj's headquarters located?

Minus sign iconPlus sign icon
Biohit Oyj's main headquarters is located at 1 Laippatie Helsinki, Southwest Finland 00880 Finland. The company has employees across 4 continents, including EuropeAsiaNorth America.

What is Biohit Oyj's official website and social media links?

Minus sign iconPlus sign icon
Biohit Oyj's official website is biohit.fi and has social profiles on LinkedIn.

What is Biohit Oyj's SIC code NAICS code?

Minus sign iconPlus sign icon
Biohit Oyj's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biohit Oyj have currently?

Minus sign iconPlus sign icon
As of March 2026, Biohit Oyj has approximately 65 employees across 4 continents, including EuropeAsiaNorth America. Key team members include Ceo: J. H.Cto: P. H.Cto, Director Operations & Ict: T. T.. Explore Biohit Oyj's employee directory with LeadIQ.

What industry does Biohit Oyj belong to?

Minus sign iconPlus sign icon
Biohit Oyj operates in the Biotechnology Research industry.

What is Biohit Oyj's email format?

Minus sign iconPlus sign icon
Biohit Oyj's email format typically follows the pattern of First.Last@biohit.fi. Find more Biohit Oyj email formats with LeadIQ.

When was Biohit Oyj founded?

Minus sign iconPlus sign icon
Biohit Oyj was founded in 1988.

Biohit Oyj

Biotechnology ResearchSouthwest Finland, Finland51-200 Employees

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com

Product range consists of products and analysis systems for the early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of fecal occult intestinal bleeding (faecal occult blood) that indicates a risk of colorectal cancer. Acetium innovation is developed to reduce carcinogenic acetaldehyde in the gastrointestinal tract. We are looking for distributors and licencing partners.

Section iconCompany Overview

Headquarters
1 Laippatie Helsinki, Southwest Finland 00880 Finland
Website
biohit.fi
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1988
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $100M$250M

    Biohit Oyj's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $100M$250M

    Biohit Oyj's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.